Physician

Dolly R. Quispe Leveau, M.D.

According to 2025 Medicare claims, Dolly Leveau, M.D. (NPI: 1821209370) practices hematology/oncology in the Fort Wayne, IN market, with the plurality of this provider's patient population coming from Allen, IN. This provider's primary affiliated billing organization is AMERICAN ONCOLOGY PARTNERS PA (NPI: 1265929723; TIN: 824681345) and primary practice location at 46825-1619. Leveau is affiliated with the Caravan Health ACO 43 LLC (ACO ID: A4974) and CoreHealth Alliance LLC (ACO ID: A5645), participating under the MSSP model.

Leveau's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 414 traditional Medicare patients, billed 64,430 HCPCS/CPT codes, and received $962,204 in Medicare payments. The top billing code was 96413 (Administration of chemotherapy into vein, 1 hour or less). Part D data shows 725 prescription claims across 184 beneficiaries totaling $2,171,374 in drug costs, led by Ojjaara (Momelotinib Dihydrochloride). 2023 DME data shows 27 claims. Open Payments data shows 51 records totaling $1,340. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $1,112,948 to $962,204. In contrast, Part D prescription costs have risen steadily, from $321,881 to $2,171,374. For DME billing, this smaller-volume category started with an early spike, then settled into a lower baseline, moving from $1,458 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	737	94,375	$1,112,948
2016	856	139,244	$1,567,207
2017	833	150,081	$1,872,019
2018	865	127,507	$1,684,827
2019	727	99,213	$1,191,908
2020	606	87,442	$1,106,059
2021	589	62,553	$914,112
2022	513	64,396	$739,459
2023	415	73,081	$931,072
2024	414	64,430	$962,204

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	211	845	$321,881
2016	237	991	$704,561
2017	218	1,047	$1,226,712
2018	258	1,184	$777,210
2019	231	1,039	$718,255
2020	211	1,031	$673,891
2021	185	838	$716,863
2022	203	887	$1,137,746
2023	193	852	$1,140,949
2024	184	725	$2,171,374

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	58	$5,763
2017	N/R	13	$6,257
2018	N/R	12	$906
2019	N/R	N/R	N/R
2020	N/R	43	$1,406
2021	N/R	39	$2,427
2022	N/R	N/R	N/R
2023	N/R	27	$2,535
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
96413	Administration of chemotherapy into vein, 1 hour or less	53	112	$89
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	193	334	$86
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	122	139	$58
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	52	105	$43
96372	Injection of drug or substance under skin or into muscle	55	121	$10

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Ojjaara	Momelotinib Dihydrochloride	13	390	$349,296
Jakafi	Ruxolitinib Phosphate	21	630	$344,137
Tagrisso	Osimertinib Mesylate	15	450	$249,092
Tasigna	Nilotinib Hcl	11	308	$109,467
Eliquis	Apixaban	73	3,450	$67,049

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	51	$1,340	PFIZER INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Dolly R. Quispe Leveau, M.D.?

Tedicare shows public-source Medicare data for Dolly R. Quispe Leveau, M.D. (NPI 1821209370), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Dolly R. Quispe Leveau, M.D. have ACO affiliation data?

Dolly R. Quispe Leveau, M.D. is shown with ACO affiliation data for Caravan Health ACO 43 LLC (MSSP, ACO ID A4974) and CoreHealth Alliance LLC (MSSP, ACO ID A5645).

What billing organization is linked to Dolly R. Quispe Leveau, M.D.?

Dolly R. Quispe Leveau, M.D. is linked to AMERICAN ONCOLOGY PARTNERS PA (billing NPI 1265929723) in the available physician profile data.

Does Dolly R. Quispe Leveau, M.D. have Open Payments data?

Dolly R. Quispe Leveau, M.D. has 51 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.